Skip to main content

Table 9 Approved cannabis-based drugs by a national regulatory authority for clinical use and related patent data

From: Trends in intellectual property rights protection for medical cannabis and related products

Drug proprietary name

Active pharmaceutical ingredient

Medical condition

Company

Country and year of approval

Relevant patents and dates of expiry

Cesamet

Nabilone (synthetic cannabinoid)

Nausea, Multiple sclerosis, Fibromyalgia

Eli Lilly, Valeant

USA, 1985,2006, UK, EU Austria, Belgium, Spain, variously from 2007

US4195078—expired 1999

EP2004075590—expired 2018

Epidiolex

Cannabidiol (CBD)

Epilepsy

GW Pharma

USA 2018

EU 2019

US10/468041—expiry date 2026

US9956185—expiry date 2035

US9066920—expiry date 2032

Marinol

Dronabinol (synthetic Tetrahydrocannabinol (THC)

HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting

Solvay Pharmaceuticals

USA 1985, 1992

US5166145—expired 2010

US6383513—expired 2018

Sativex

THC and CBD in a 1:1 ratio

neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis

GW Pharma

UK 2010 and various European countries, Canada 2005

US20060135599A1—expiry date 2022

US10538373—estimated expiry date 2022

Syndros

Synthetic THC (Dronabinol) in liquid formulation for oral administration

Nausea and vomiting caused by chemotherapy, loss of appetite

Insys Therapeutics

US 2016

US9345771—expiry date 2028

US8222292—expiry date 2028